Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting
Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)
Christine Xu¹, Patrick Nolain ², Qiang Lu ³, Anne Paccaly ⁴, Melitza Iglesias-Rodriguez ⁵, Gregory St John ⁶, Chad Nivens ⁴, Rafael Maldonado ⁷, Tomonori Ishii ⁸, Ernest Choy ⁹ and Vanaja Kanamaluru ³, ¹Sanofi, Bridgewater, NJ, ²Sanofi-Aventis, Montpellier, France, ³Sanofi, Bridgewater, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Pompeu Fabra University, Barcelona, Spain, ⁸Tohoku University Hospital, Sendai, Japan, ⁹Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…
Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
Gerd R. Burmester¹, Frank Buttgereit¹, Corrado Bernasconi², Jose Maria Alvaro-Gracia³, Nidia Castro², Maxime Dougados⁴, Cem Gabay⁵, Jacob van Laar⁶, J. Michael Nebesky², Attila Pethö-Schramm², Carlo Salvarani⁷, Marc Y. Donath⁸ and Markus R. John², ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Hospital Universitario de La Princesa IIS-IP, Madrid, Spain, ⁴Université Paris-Descartes, Paris, France, ⁵University Hospitals of Geneva, Geneva, Switzerland, ⁶University Medical Centre Utrecht, Utrecht, Netherlands, ⁷Università de Modena e Reggio Emilia, Modena, Italy, ⁸University Hospital Basel, Basel, Switzerland
Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2 but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…
Abstract Number: 570 • 2018 ACR/ARHP Annual Meeting
Evaluation of CXCL13, sICAM1, MMP-3 and S100A8/A9 As Serum Biomarkers in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab
D. James Haddon, Thierry Sornasse, Michael J. Townsend, Jinglan Pei and Margaret Michalska, Genentech, Inc., South San Francisco, CA
Background/Purpose: Serum levels of C-X-C motif chemokine ligand 13 (CXCL13) and soluble intercellular adhesion molecule-1 (sICAM-1) have been associated with outcomes in patients with rheumatoid…
Abstract Number: 572 • 2018 ACR/ARHP Annual Meeting
Combining Tocilizumab with Methotrexate Improves Sustainability. Real World Evidence Report from Quebec Database Rhumadata®
Denis Choquette¹, Louis Bessette², Jacques Brown², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Angèle Turcotte², Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: Biologic therapy targeting TNF have consistently demonstrated better efficacy and effectiveness when combined with a conventional synthetic DMARD (csDMARD), most frequently methotrexate. Although pre-clinical…
Abstract Number: 573 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis
Pascal Hilliquin¹, Thomas Barnetche², Guy Baudens³, Ralph Niarra⁴, Isabelle Idier⁵ and Alain Saraux⁶, ¹Rheumatology, Hôpital Sud Francilien, Corbeil-Essonne, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHR Valenciennes, Valenciennes, France, ⁴Biostatistics, Keyrus of behalf of Roche SAS, Boulogne-Billancourt, France, ⁵Medical department, Chugai Pharma France, Paris La Defense, France, ⁶Rheumatology, CHU Brest, Brest, France
Background/Purpose: In France, tocilizumab (TCZ) subcutaneous (sc) 1st prescription and yearly renewal are restricted to hospital. Monitoring may be done by both office-based or hospital…
Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting
Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE
Anne C. Bay-Jensen¹, Christian S. Thudium¹, Claus Christiansen² and Morten A. Karsdal¹, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
Abstract Number: 615 • 2018 ACR/ARHP Annual Meeting
The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis
Mayumi Matsuda¹, Yu Funakubo Asanuma², Yoshinobu Nakao³, Hiroaki Yazawa², Takuma Tsuzuki Wada⁴, Noritsune Kouzu⁵ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology, Saga University Hospital, Saga, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, ⁵Saitama Medical University, Moroyama, Japan
Background/Purpose: Since 2003 in Japan, biologic agents have become widely used for RA patients in whom csDMARDs were ineffective. Tocilizumab (TCZ) was approved for marketing…
Abstract Number: 958 • 2018 ACR/ARHP Annual Meeting
Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting
Fenglong Xie¹, Huifeng Yun¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Multiple studies have observed unfavorable changes in lipid profile associated with tocilizumab (TCZ, anti-IL6 receptor antagonists) and some other rheumatoid arthritis (RA) therapies. The…
Abstract Number: 1174 • 2018 ACR/ARHP Annual Meeting
Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis
Jennie H. Best and Jinglan Pei, Genentech, Inc., South San Francisco, CA
Background/Purpose: The cost-effectiveness of different biologic therapies is an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA). The objective of this…
Abstract Number: 1514 • 2018 ACR/ARHP Annual Meeting
Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis
Dimitrios A. Pappas¹, Carol J. Etzel², Margaux Crabtree³, Jennie H. Best⁴, Steve Zlotnick⁴ and Joel Kremer⁵, ¹Columbia University, New York, NY, ²Corrona LLC, Waltham, MA, ³Corrona, LLC, Waltham, MA, ⁴Genentech, Inc., South San Francisco, CA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Few real-world studies have evaluated the impact of comorbidity burden or obesity on the effectiveness of tocilizumab (TCZ) for the improvement of rheumatoid arthritis…
Abstract Number: 1543 • 2018 ACR/ARHP Annual Meeting
The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis
Takuma Tsuzuki Wada¹, Yu Funakubo Asanuma², Mayumi Matsuda³, Hiroaki Yazawa², Yoshinobu Nakao⁴, Noritsune Kozu⁵ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ⁴Department of Rheumatology, Saga University Hospital, Saga, Japan, ⁵Kozu Orthopedic Clinic, Yachiyo, Japan
Background/Purpose: Elderly patients with rheumatoid arthritis (RA) have declined physical performances and increased various complications. We are concerned about decrease of efficacy and increase of…
Abstract Number: 447 • 2017 ACR/ARHP Annual Meeting
Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis
Levent Kilic¹, Orhan Kucuksahin², Zeynep Ozbalkan³, Cemal Bes⁴, Veli Yazisiz⁵, Ayten Yazici⁶, Dilek Solmaz⁷, Timucin Kasifoglu⁸ and Umut Kalyoncu⁹, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ³Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, ⁴Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁵Rheumatology, Akdeniz University Faculty of Medicine, Ankara, Turkey, ⁶Department of Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, ⁷Rheumatology, Katip Çelebi University Faculty of Medicine, İzmir, Turkey, ⁸Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ⁹Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: In general, retention rate in biological DMARDs represent both efficacy and safety. Tocilizumab (TOC) is a humanized monoclonal antibody that binds to the interleukin-6…
Abstract Number: 2469 • 2017 ACR/ARHP Annual Meeting
Median Time to Lda Is Shorter in Tocilizumab Combination Therapy with Csdmards As Compared to Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Responses to Csdmards and/or TNF Inhibitors: Sub-Analysis of the Swiss and Austrian Patients from the ACT-SURE Study
Ruediger Mueller¹, Winfried Graninger², Páris Sidiropoulos³, Christoph Goger⁴ and Johannes von Kempis⁵, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³F. Hoffmann-La Roche Ltd, South San Francisco, CA, ⁴Roche Austria GmbH, Vienna, Austria, ⁵Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: To analyze efficacy and safety of tocilizumab in patients with rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease modifying anti-rheumatic drugs…
Abstract Number: 453 • 2017 ACR/ARHP Annual Meeting
The Therapy with Tocilizumab Is Not Associated with Periarticular Demineralisation and Finger Joint Space Narrowing in Rheumatoid Arthritis
Alexander Pfeil¹, Ottar Gadeholt², Joachim Böttcher³, Diane Renz⁴, Peter Oelzner¹ and Gunter Wolf¹, ¹Department of Internal Medicine III, Jena University Hospital, Jena, Germany, ²Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ³Institut of Interventional and Diagnostic Radiology, SRH Waldklinikum Gera, Gera, Germany, ⁴Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Jena, Germany
Background/Purpose: Digital X-ray Radiogrammetry (DXR) and Computer-Aided Joint Space Analysis (CAJSA) are established computer based techniques for the quantification of metacarpal bone mineral density and…
Abstract Number: 2474 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Extending Tocilizumab Infusion Intervals from 4 Weeks to 6 Weeks in Patients with Rheumatoid Arthritis
Hiroshi Uda¹ and Osamu Saiki², ¹Rheumatology, Higashiosaka City Medical Center, Higashiosaka, Japan, ²Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose : A period of 4 weeks (w) has been recommended for rheumatoid arthritis (RA) patients as the interval between tocilizumab (TCZ, 8mg/kg) infusions. However,…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].